WALTHAM, Mass., Nov. 8 /PRNewswire/ -- AltaRex Corp. (AXO.TO, ALXFF.OTC),
a developer of foreign antibodies that activate the immune system to treat
cancer, announced that the data from the Company's OvaRex(R) clinical
development program for the treatment of advanced ovarian cancer are being
presented today at the 19th Annual Chemotherapy Foundation Symposium by
Jonathan Berek, M.D., Chief of the Division of Gynecology and Oncology, UCLA
School of Medicine.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000831/ALTREXLOGO )
Dr. Berek is a leading researcher in the field of biologic treatments for
gynecologic cancers with a particular interest in those that activate natural
cancer killing capabilities of the human immune system. He is one of the
leading authorities and proponents of immunotherapy for the treatment of
ovarian cancer and has a distinguished career in such research. Dr. Berek is
the co-principal investigator of the Company's lead pivotal 345-patient
OvaRex(R) clinical trial, which is complete for primary analysis pending study
unblinding.
"For those of us who have been involved in immunologic and biologic
research for the past couple of decades, this represents a very exciting time.
I think ovarian cancer ultimately will be one of those cancers where
immunotherapy could be very valuable," comments Dr. Berek. "In large part,
monoclonal antibodies have been disappointing, but the OvaRex(R) antibody has
been well tolerated by patients in the OvaRex(R) clinical trials and takes a
novel approach to activating immunity -- it is one of the most promising
biologics for ovarian cancer patients," added Dr. Berek.
The Company expects to announce the primary results of the lead trial by
year-end, and depending on such results, to file a Biologics License
Application (BLA) with the U.S. Food and Drug Administration (FDA) seeking
approval of OvaRex(R) MAb as treatment for ovarian cancer patients in
remission and as a benign stand-alone and/or consolidation therapy for the
treatment of recurrent disease.
The Chemotherapy Foundation Symposium gathers leading medical oncologists
and hematologists in New York City from around the globe to explore the
significance of new developments and the challenge of broadening therapeutic
options for the management of cancer patients. This year's symposium, titled
Innovative Cancer Therapy for Tomorrow, reports on progress in converting
cancer from a life-threatening disease to a treatable chronic illness.
More about AltaRex research and development of foreign antibodies that
activate the immune system, the Company's clinical trials, news and events can
be found at http://www.altarex.com.
This news release contains forward-looking statements that involve risks
and uncertainties, which may cause actual results to differ materially from
the statements made. For this purpose, any statements that are contained
herein that are not statements of historical fact may be deemed to be forward-
looking statements. Without limiting the foregoing, the words "believes,"
"anticipates," "plans," "intends," "expects" and similar expressions are
intended to identify forward-looking statements. Such risks and uncertainties
include, but are not limited to our need for capital and the risk that the
Company can not raise funds on a timely basis on satisfactory terms or at all,
changing market conditions, uncertainties regarding the timely and successful
completion of clinical trials, patient enrollment rates, uncertainty of pre-
clinical, retrospective, early and interim clinical trial results, which may
not be indicative of results that will be obtained in ongoing or future
clinical trials, whether the Company will file for regulatory approval on a
timely basis, uncertainties as to when, if at all, the FDA will approve the
Company's regulatory filings for its products, the need to establish and
scale-up manufacturing processes, the need to obtain and maintain corporate
alliances, uncertainty as to the timely development and market acceptance of
the Company's products, uncertainty as to whether patents will issue from
pending patent applications and, if issued, as to whether such patents will be
sufficiently broad to protect the Company's technology, and other risks
detailed from time-to-time in the Company's filings with the United States
Securities and Exchange Commission and Canadian securities authorities. The
Company does not assume any obligation to update any forward-looking
statement.
THE TORONTO STOCK EXCHANGE HAS NOT APPROVED OR DISAPPROVED OF THE
INFORMATION CONTAINED HEREIN
SOURCE AltaRex Corp.
 back to top
Related links:
http://www.altarex.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/20000831/ALTREXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/128163.html
CONTACT:
Sondra Henrichon, Director, Investor
Relations and Corporate Communications of AltaRex Corp.,
+1-781-672-0138, ext. 1510, shenrichon@altarex.com; or Wayne
Hendry, Investor Relations of The Equicom Group Inc.,
+1-416-815-0700, ext. 238, whendry@equicomgroup.com
|
